Explore the Research Library
Search and filter the complete research collection.
Search Results
FAQ
Common questions about oculomics research and clinical validation
Oku is a healthcare data and AI platform that connects the eye to the rest of the body. Built on Topcon Healthcare's ophthalmic device network, Oku turns ophthalmic data into insight for pharma, providers, and researchers, one connected loop instead of siloed and disconnected data across various vendors. The result is a connected network that unlocks the value of routine exams to support earlier disease detection, better care pathways, and accelerated healthcare innovation.
Real-world data (RWD) is health information collected outside a clinical trial, from routine care, imaging, claims, and patient records. Real-world data reflects how patients are actually diagnosed and treated in everyday practice, not just under controlled trial conditions. At Oku, real-world data includes the rich biological signals captured through routine eye exams. By connecting ophthalmic data with broader healthcare information, Oku helps transform these everyday clinical interactions into a valuable resource for research, care improvement, and healthcare innovation.
Real-world evidence (RWE) is the clinical insight generated by analyzing real-world data. Where real-world data is the raw material, real-world evidence is the conclusion, how a disease progresses, how a treatment performs, or who's most likely to benefit, drawn from real patient populations rather than trial cohorts alone. At Oku, we believe some of healthcare's most valuable real-world evidence begins with the eye. By unlocking biological signals from routine eye exams and connecting them across the healthcare ecosystem, Oku helps transform ophthalmic data into evidence that can advance research, accelerate innovation, and improve patient outcomes.
Ophthalmic data is valuable for healthcare research because the eye is the only place in the body where blood vessels and nerve tissue can be observed directly and non-invasively. This makes ophthalmic imaging an early window into systemic conditions, cardiovascular, neurological, and metabolic disease can all show signals in the eye before they're diagnosed anywhere else.
AI helps analyze ophthalmic data by processing retinal images at a scale and speed no reading center could match manually. AI-driven analysis identifies patterns across thousands of scans to flag disease markers, quantify risk, and surface signals that aren't visible to the eye alone, turning a single scan into a much richer dataset. Within the Oku ecosystem, AI serves as a key engine for turning routine exams into actionable healthcare intelligence.
Diseases studied using ophthalmic data include diabetic retinopathy, age-related macular degeneration, and glaucoma, as well as systemic conditions with retinal signatures such as cardiovascular disease, diabetes, and certain neurological conditions.
Oku supports clinical research by combining ophthalmic imaging, AI-driven data analysis, reading center expertise, patient-finding, and real-world evidence generation in one connected platform, replacing what typically requires multiple separate vendors. This means faster cohort identification, richer longitudinal data, and evidence built around the patients researchers actually need.
Real-world ophthalmic data can be used in drug development to identify eligible patients, characterize disease progression, and generate evidence that complements traditional clinical trial data. In ophthalmology and beyond, real-world data helps pharma understand how a treatment performs across broader, more diverse populations than a trial alone can capture.
Compliance-native data is built with regulatory and privacy requirements embedded from the point of collection, rather than added after the fact. This matters in healthcare research because data that isn't compliance-native often can't be used for regulatory submissions or multi-site research without significant rework.
Oku is designed with privacy and security principles that support healthcare compliance requirements, including HIPAA standards for safeguarding protected health information.
Harmony® is Oku's connected care platform that transforms routine eye exams into actionable healthcare insights. By bringing together ophthalmic imaging, patient data, referrals, AI applications, and care teams in a single secure environment, Harmony helps connect eye care with primary care and specialty care, supporting earlier intervention, more coordinated care pathways, and better healthcare outcomes.
21 CFR Part 11 is an FDA regulation governing electronic records and electronic signatures used in regulated environments. Compliance helps support data integrity, traceability, and audit readiness.
Oku supports data quality through standardized imaging protocols, AI-assisted review, and reading center oversight, ensuring ophthalmic data is consistent and research-ready rather than raw and unverified. Data quality is what allows real-world evidence to hold up to regulatory and scientific scrutiny.
Providers may benefit from improved care coordination, stronger data connectivity, and opportunities to contribute to research that advances the understanding and treatment of eye disease.
Oku connects eye care and primary care by turning retinal imaging into systemic health signals that can inform care beyond the eye exam. A diabetic retinopathy screening, for example, can also flag cardiovascular risk, closing a gap that typically exists between eye care and primary care records. By connecting these insights across the healthcare ecosystem, Oku helps turn the eye exam into a new front line for broader health assessment and care coordination.
Retinal imaging is important beyond eye health because the retina is the only place in the body where blood vessels and nerve tissue can be observed directly and non-invasively. This gives retinal imaging value as an early indicator for cardiovascular, neurological, and metabolic disease, not just ocular conditions. As a result, retinal images can reveal biological signals associated with cardiovascular, neurological, and metabolic conditions, in addition to ocular disease.
Oku supports precision medicine by using AI-driven analysis of ophthalmic data to identify patient-specific risk patterns and disease subtypes. Precision medicine depends on rich, well-characterized patient data, and connected ophthalmic and systemic data is a source that's been largely underused.
Healthcare interoperability is the ability of different health systems, devices, and data sources to exchange and use information seamlessly. In ophthalmology, interoperability means imaging data, reading center findings, and patient records can work together instead of remaining siloed across separate vendors.
Oku contributes to healthcare innovation by unifying ophthalmic imaging, AI analysis, and real-world evidence generation into a single connected platform. Ophthalmic data has historically been an underused resource in broader healthcare research, and Oku is built to change that.
Traditional healthcare data platforms often aggregate information after it has already been collected across fragmented systems. Oku starts with a unique source of biological insight: the eye. By combining ophthalmic data, AI, connected care networks, and research capabilities, Oku helps create a continuous intelligence layer that links providers, patients, researchers, and industry.
Healthcare from the Eye reflects Oku's vision that the eye can serve as an accessible front door to broader health insights. By unlocking biological signals from routine eye exams and connecting them across the healthcare ecosystem, Oku is helping create new opportunities for earlier detection, more coordinated care, and improved health outcomes.